Systemic sclerosis & Raynaud's
Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual
Authors' conclusion
In this retrospective observational cohort study, using IPTW to adjust for confounders, we found a protective effect of receiving ISs on damage accrual in patients with lcSSc.
Study context
- Population
- Patients with early systemic sclerosis (SSc) (≤2 years disease duration), limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), Canadian and Australian cohortslcSSc 210
- Exposure
- Ever vs never exposed to immunosuppressive drugs, separately in lcSSc and dcSSc
- Outcome
- Global organ damage (Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI))
Methodological detailsinverse probability of treatment weighting (IPTW), marginal structural generalized estimating equation model, Canadian and Australian cohorts
- Inverse probability of treatment weighting (IPTW)
- Marginal structural generalized estimating equation model
- Canadian and Australian cohorts
Main finding
As reported in the abstract
Damage scores (SCTC-DI)
- lcSSc (n=210; 34% exposed to ISs): IS exposure associated with lower damage scores
- dcSSc (n=192; 76% exposed to ISs): IS exposure not associated with damage scores
- IPTW-adjusted
Observational data: associations, not effects.
Original publication
Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual. Arthritis Care Res (Hoboken). Published 2 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →